Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.32 |
| ▸ | PNMT | P11086 | 3/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | ENTPD5 | O75356 | 1/20 | 0.31 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8539054 | 0.85 | PBRM1 (0.35) | ADRA2APNMTADRA2BADRA2CBACE1 | |
| SCHEMBL8536924 | 0.74 | ENTPD5 (0.34) | ADRA2APNMTADRA2BADRA2CBACE1 | |
| SCHEMBL8513012 | 0.72 | ALDH1A1 (0.39) | — | |
| SCHEMBL8513008 | 0.72 | ALDH1A1 (0.39) | — | |
| SCHEMBL8513011 | 0.72 | ALDH1A1 (0.39) | — | |
| SCHEMBL8532278 | 0.69 | BACE1 (0.33) | BACE1PBRM1 | |
| SCHEMBL9633675 | 0.67 | HIF1A (0.52) | ADRA2APNMTADRA2BADRA2CPBRM1 | |
| SCHEMBL9931351 | 0.64 | PBRM1 (0.38) | BACE1PBRM1 | |
| SCHEMBL828814 | 0.64 | FAAH (0.39) | ADRA2APNMTADRA2BADRA2CBACE1 | |
| SCHEMBL8679978 | 0.64 | METAP1 (0.39) | ADRA2APNMTADRA2BADRA2CPBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012071458-A1 | HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | ADRA2A 3254/4885PNMT 1564/4885ADRA2B 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.